Gilead Sciences, Inc. (GILD)

jimsfordgt40 (< 20) Submitted: 11/16/07 11:33 PM : Start Price: $44.58 GILD Score: 40.30

Sales of Truvada, Viread, Atripla, and Emtriva for the treatment of HIV will continue to grow. GILD trades at a premium to the biotechnology sector based on earnings. But you can't judge biotech or pharma on earnings. It's all about the pipeline and what's ready for approval.

For now, I think GILD should be at $50 or $51 in a year, but any new developments in the pipeline will boost the price. Great upside and limited downside.

Report this Post Replies: 0 | Reply | Permalink